Table 1_Autologous regenerative cell therapy for female stress urinary incontinence: a sys

A 2026 systematic review and meta-analysis by Jiemei Chen, aggregating data from 19 studies involving 591 patients. The dataset compiles clinical outcomes, including cure and improvement rates, pad test results, leakage frequency, and quality-of-life scores, to evaluate the efficacy and safety of autologous regenerative cell therapy for female stress urinary incontinence.

Use Cases

• Evaluating the pooled efficacy of regenerative cell therapy based on reported cure and improvement rates.
• Analyzing treatment safety profiles based on compiled adverse event and loss-to-follow-up rates.
• Assessing changes in patient-reported outcomes based on incontinence-specific questionnaire and quality-of-life scores.
• Investigating heterogeneity in clinical trial results based on the subgroup and sensitivity analyses described.

Strengths

• Includes data from 19 studies encompassing 591 patients, providing a quantitative synthesis of the field.
• Reports specific pooled outcome rates, including a 41% cure rate and 55% improvement rate.
• Analyzes multiple secondary outcomes including urodynamic parameters, pad tests, and quality-of-life measures.
• Dataset is openly licensed under CC-BY-4.0, facilitating reuse and sharing.

Limitations

• Row count and column-level documentation are unknown, requiring manual inspection after download to understand data structure.
• The underlying studies are described as having short follow-up, significant heterogeneity, and low-to-moderate quality, which may limit the strength of conclusions.
• The dataset is very small at 9.9 KB, indicating a limited scope focused on aggregated summary statistics rather than individual patient data.

Provenance

Source

figshare, authored by Jiemei Chen.

Collection Method

Systematic review and meta-analysis of studies from PubMed, Web of Science, EMBASE, Cochrane Library, and CINAHL databases.

Freshness

Last updated 2026-06-03 04:47:23.